title: [Potential hemoprotective effect of dicarbamin in chemoradiotherapy for malignant tumors].
abstract: To improve the results of treatment of locally advanced malignant tumors we performed different types of combined radio- and chemotherapy, which are mostly applied in neo- and/or adjuvant or parallel regimens, and have significant toxic effect on hemopoiesis. For the last years we have used dicarbamin, a natural hemoprotector from the group of pseudopeptides. Good outcomes have been achieved in its ability to reduce frequency of hematological complications in patients with locally advanced lung cancer and Hodgkin's disease treated by combined radio- and chemotherapy.
authors.forename: F R
authors.initials: FR
authors.lastname: Dzhabarov
authors.forename: L Ia
authors.initials: LIa
authors.lastname: Rozenko
authors.forename: N K
authors.initials: NK
authors.lastname: Gus'kova
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects*; D002208:Caproates; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D020011:Protective Agents / Q000627:therapeutic use*; D018714:Radiotherapy, Adjuvant / Q000009:adverse effects; D012189:Retrospective Studies
chemical_list: D002208:Caproates; D007093:Imidazoles; D020011:Protective Agents; C539419:pentanedioic acid imidazolyl ethanamide